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O B J E C T I V E S We sought a method for any reader to quantify the limit, imposed by variability, to
sustainably observable R2 between any baseline predictor and response marker. We then apply this to
echocardiographic measurements of mechanical dyssynchrony and response.
B A C KG ROUND Can mechanical dyssynchrony markers strongly predict ventricular remodeling by
biventricular pacing (cardiac resynchronization therapy)?
METHOD S First, we established the mathematical depression of observable R2 arising from:
1) spontaneous variability of response markers; and 2) test–retest variability of dyssynchrony measurements.
Second, we contrasted published R2 values between externally monitored randomized controlled trials and
highly skilled single-center studies (HSSCSs).
R E S U L T S Inherent variability of response markers causes a contraction factor in R2 of 0.48 (change
in left ventricular ejection fraction [∆LVEF]), 0.50 (change in end-systolic volume [∆ESV]), and 0.40 (change
in end-diastolic volume [∆EDV]). Simultaneously, inherent variability of mechanical dyssynchrony markers
causes a contraction factor of between 0.16 and 0.92 (average, 0.6). Therefore the combined contraction
factor, that is, limit on sustainably observable R2 between mechanical dyssynchrony markers and
response, is 0.29 (∆LVEF), 0.24 (∆ESV), and 0.30 (∆EDV). Many R2 values published in HSSCSs
exceeded these mathematical limits; none in externally monitored trials did so. Overall, HSSCSs
overestimate R2 by 5- to 20-fold (p  0.002). Absence of bias-resistance features in study design (formal
enrollment and blinded measurements) was associated with more overstatement of R2.
CONC L U S I O N S Reports of R2 0.2 in response prediction arose exclusively from studieswithout formally
documented enrollment and blinding. The HSSCS approach overestimates R2 values, frequently breaching the
mathematical ceiling on sustainably observable R2, which is far below 1.0, and can easily be calculated by readers
using formulas presented here. Community awareness of this low ceiling may help resist future claims. Reliable
individualized response prediction, using methods originally designed for group-mean effects, may never be
possible because it has 2 currently unavailable and perhaps impossible prerequisites: 1) excellent blinded
test–retest reproducibility of dyssynchrony; and 2) responsemarkers reproducible over timewithin nonintervened
individuals. Dispassionate evaluation, and improvement, of test–retest reproducibility is required before any
further claims of strong prediction. Prediction studies should be designed to resist bias. (J Am Coll Cardiol Img
2012;5:1046–65) © 2012 by the American College of Cardiology Foundation
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1047iventricular pacing is thought to deliver
benefit in heart failure through resynchroni-
zation of dyssynchronous cardiac mechani-
cal function, hence the term cardiac resyn-
chronization therapy (1–6). Some studies (7–9)
demonstrate strong relationships (high coefficient
of determination, R2 values) between baseline me-
chanical dyssynchrony and echocardiographic out-
come measures, whereas others (10–12) show much
weaker relationships. Most guidelines for selecting
patients for biventricular pacing emphasize electri-
cal dyssynchrony manifested as wide QRS duration
rather than mechanical dyssynchrony (13), although
pressure is growing from increasing numbers of
positive studies reporting an association between
baseline dyssynchrony and ventricular response.
One country’s guidelines already include mechani-
cal dyssynchrony in selection (14).
Tantalizing glimpses of reliable prediction of
response continue to drive the search for mechani-
cal dyssynchrony markers or multivariate combina-
tion algorithms to provide better prediction. But is
this approach wise? Why do studies disagree? Re-
ports of R2 exceeding 1.0 would be recognized as
incorrect, but is the real upper limit of sustainably
observable R2 really 1.0, or something lower? How
can one calculate the highest plausible R2 between
dyssynchrony and response? How should we inter-
pret this clinically, and does it affect how we design
future research?
The ceiling on R2 depends upon natural variabil-
ty of dyssynchrony markers and of response markers.
linded test–retest reproducibility data on mechanical
yssynchrony markers (15,16) and commonly used
utcome markers of reverse remodeling are scarce. In
his study we collate these and thereby calculate the
rue upper limit on plausible sustainably observable R2
between dyssynchrony markers and echocardiographic
response.
We evaluate the implications for design and
interpretation of studies seeking clinically reliable
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M E T H O D S
Quantitative separation of device-mediated, versus
spontaneous, changes in left ventricular ejection
fraction (LVEF). Randomized trials of biventricular
acing are the best way to separate spontaneous
hanges from device-induced changes in cardiac
unction. Patients undergoing biventricular pacing
ave 2 drivers of pre-to-post change in the chosen
chocardiographic outcome measure (e.g., change
n left ventricular ejection fraction [LVEF]). First,
nherent phenomena unrelated to biventricular pac-
ng, including true biological variability and measure-
ent error, will contribute to individual patients’
LVEF. The variance (square of standard
eviation [SD2]) of LVEF in the control
atients in a randomized trial measures the
ize of this inherent scatter between succes-
ive measurements over time. Second, the
evice itself imposes an effect over and above
he inherent variation. Because different pa-
ients (presumably) gain different amounts
f effect from the device, LVEF is more
idely spread in the device patients than the
ontrol patients. The extra variance in
LVEF in the device patients is the variance
aused by the device (Fig. 1). Only this extra
ariance, caused by the device, has any hope
f being predicted by baseline dyssynchrony.
Meanwhile, baseline dyssynchrony markers
lso have inherent variability within a given patient
ver time. Only test–retest reproducibility studies
eveal the extent of this. This is also true of
ultivariate combination algorithms used to score
yssynchrony because each component contributes
omething to inherent variability.
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1048When correlating (r) two variables, such as mechanical
dyssynchrony and echocardiographic response, or deter-
mining the predictive value of one on the other (R2), the
measurement variability of both combine to depress the
observable relationship strength (Fig. 2) (17). We term
this the R2 contraction factor because of the following
elationship (Equation 1):
Observed R2Underlying R2  R2 Contraction Factor [1]
where underlying R2 is the potential correlation
over
nths
No
intervention
Unpredictable &
nothing to do
with CRT
CRT
Potentially
predictable
component
of variability
“Unpredictable &
nothing to do with CRT”
component of
variability
-10
0
+10
over
nths
SD ∆ is much larger in CRT arm:
Large scope for predictability
of response
SD ∆ is not much larger in CRT arm:
Little scope for predictability
of response
-10
0
+10
over
nths
-10
0
+10
e 1. Only Part of the Spectrum of Response in the Intervention
Is Attributable to the Intervention
l populations in randomized controlled trials of cardiac resynchronisa-
erapy (CRT) have changes in their outcome markers (e.g., left ventricular
n fraction [LVEF], left ventricular end-systolic volume [LVESV], and left
ular end-diastolic volume [LVEDV]) even without intervention. This
e is inherent and unpredictable but can be measured by the variance
e of standard deviation [SD2]) of the change in LVEF (∆LVEF) (top row,
nel). Those undergoing CRT have a further change in LVEF over and
inherent changes, widening the spread or variance in ∆LVEF (top row,
anel). Only the incremental change above inherent change is attribut-
the device and only this component of variance of ∆LVEF is predict-
y any baseline marker. (Although it is the variances of ∆LVEF that mat-
e ﬁgure displays SDs as a visual proxy.) When the SD of the ∆LVEF (SD∆)
h larger in the biventricular pacing arm of a trial than in the control arm
le row), there is good scope for predicting response. When the SD∆ is
uch larger in the biventricular pacing arm than in the control arm
m row), the scope for predictability is much smaller.between the variables if all measurement noisecould be eradicated. The online appendix shows
full details. The R2 contraction factor is also a
eiling on sustainably observable R2 values be-
cause the underlying R2 cannot exceed 1.0.
The R2 contraction factor has 2 contributors:
1) contraction from response irreproducibility;
and 2) contraction from dyssynchrony irrepro-
ducibility. Both are easy to calculate if data are
available. Calculating the R2 contraction factor
rising from response irreproducibility requires
he SD of the  in the outcome measure in both
he control arm and device arm of a randomized
ontrol trial. It is not sufficient to know the
istribution of the initial and final LVEFs.
ather, the distribution of the change, that is, the
SD of , is needed. This can be used in the
following calculation (Equation 2):
R2 contraction factor caused by inherent
variability in response variable
1  SDcontrol armSDintervention arm
2
[2]
A similar formula is used for the mechanical dys-
synchrony measure. The 2 contraction factors are
then multiplied to determine the combined con-
traction factor (Equation 3).
Observed R2
Underlying R2
Combined R2 Contraction Factor
R2 contraction factor
imposed by
Dyssynchrony Marker

R2 contraction factor
imposed by
Response Marker
[3]
The MIRACLE-ICD II (Multicenter InSync ICD
Randomized Clinical Evaluation II) trial (18) can
be used as a worked example. In the control arm,
LVEF has an SD of 6.2; in the biventricular
pacing arm, LVEF has an SD of 8. Therefore, the
contraction factor imposed on R2 by the response
arker LVEF is 1 – (6.2/8)2  0.40. Thus in
populations like those in MIRACLE-ICD, even
with an imaginary perfectly comprehensive and
perfectly reproducible dyssynchrony marker, the
highest R2 that could be sustainably observed with
LVEF would be 0.40.
In reality, mechanical dyssynchrony markers or
scores do not have perfect test–retest reproduc-
ibility and so impose their own contraction fac-
tor. If, for example, the dyssynchrony marker
imposed a contraction factor of 0.50, then the
combined contraction factor would be 0.40 ∆EF 
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1049is completely comprehensive in describing all
aspects of dyssynchrony (and there are no con-
founding features, e.g., scar or lead position), the
maximum R2 observable is still only 0.20.
Data extraction from published studies. A systematic
review of studies assessing the response to biven-
tricular pacing was performed using the EMBASE
and MEDLINE databases (Fig. 3). The terms
cardiac resynchronization therapy, biventricular pac-
ing, and dyssynchrony were used and abstracts re-
viewed for relevance.
All published studies that assessed mechanical
dyssynchrony markers against LVEF, LV end-
systolic volume (ESV), and LV end-diastolic vol-
ume (EDV) were analyzed and had R2 data ex-
racted (7–9) (Online Appendix References 1–40).
2 was calculated where necessary by squaring the
correlation coefficient between the mechanical dys-
synchrony marker and outcome measure, using the
published data in tabular, text, or graphic form.
Weighted averages of the R2 were calculated using
the size of the study.
Studies reporting mechanical dyssynchrony
markers were assessed to determine the test–retest
variability of the markers and whether data were
Imaginary noise-free measurement
of dyssynchrony and of ∆EF
Dyssynchrony
Marker
A ∆EF
∆EF
R2 = 1
Imaginary noise-free measurement of ∆EF, 
but some measurement noise in dyssynchrony
Dyssynchrony
Marker
C
R2 = 0.7
Figure 2. How Inherent Variability in 2 Measures Reduces the M
Imagine a universally comprehensive dyssynchrony marker that can
somehow be eliminated (A). In practice there is natural variability in
marker (C). These noise properties combine together multiplicativel
case, it is mathematically impossible for an R2 value over 0.56 to becollected after formal enrollment with blinding. wStudies that report SD within 1 patient and the SD
across the population can have the R2 contraction
actor from the mechanical dyssynchrony marker
alculated as 1 – (SDwithin-patient/SDbetween-patient)
2.
Where test–retest variability is given as a correlation
coefficient r, it was used as an estimate of the R2
contraction factor imposed by the dyssynchrony
marker.
The landmark externally monitored randomized
controlled trials (EM-RCTs) of biventricular pac-
ing were assessed to determine the SD of LVEF,
LVESV, and LVEDV in the control and inter-
ention arms (Online Appendix References 41–58).
his enabled calculation of contraction factors of
hese response markers from rigorously performed,
ormally recruited, externally monitored heart fail-
re populations.
Statistics. Values are shown as mean (95% confi-
dence interval [CI]), except where otherwise indi-
cated. Comparisons between classes of study were
made using the Student unpaired t test and the
ann-Whitney U test. A p value 0.05 was
re-defined as statistically significant. Stata/SE ver-
ion 10.0 (StataCorp LP, College Station, Texas)
aginary noise-free measurement of dyssynchrony,
but some measurement noise in ∆EF
Dyssynchrony
Marker
B ∆EF
R2 = 0.8
surement noise in both dyssynchrony and ∆EF
Dyssynchrony
Marker
D ∆EF
R2 = 0.56
mum Achievable R2 Between Them
fectly predict response, as long as measurement noise could
asurements of ejection fraction (B) and of the dyssynchrony
depress the actually observable R2 value (D). In this example
served sustainably.Im
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1050R E S U L T S
Reported R2 for echocardiographic response in
M-RCTs and highly skilled single-center studies.
Fifty-eight reports were identified and assessed.
The majority were retrospective cohort studies with
or without a control group, performed in highly
skilled single centers (HSSC) with specific interest
in echocardiographic dyssynchrony markers and a
track record of innovation in the field (Online
Appendix references 41–58). The reported R2 in
hese studies between individual dyssynchrony
arkers and echocardiographic response to biven-
ricular pacing (LVEF, LVESV, or LVEDV)
re tabulated in Table 1.
R2 values were weighted according to etiology of
eart failure (ischemic heart disease vs. idiopathic);
o statistically significant difference was found be-
ween the 2 groups (p  0.38).
EM-RCTs establishing the use of biventricular
acing were assessed. Primary and secondary pub-
ications report a wide variety of potential R2
ac resynchronization
therapy”
OR 
entricular pacing”
AND 
synchrony marker”
592 records:
EMBASE 360
Medline 232
Limit to English: 51 excluded
Limit to Human: 125 excluded
177 Duplicates removed
 Full-Text articles
ssed for eligibility
 included articles
Systematic Search Strategy
tic review of the literature was undertaken to identify studies
line echocardiographic mechanical dyssynchrony markers to pre-
e in echocardiographic response markers (∆LVEF, ∆LVESV, and
bbreviations as in Figure 1.between the outcome of biventricular pacing andbaseline measures of dyssynchrony (Table 1) (On-
line Appendix references 41–58). The reported R2
values found in EM-RCTs were significantly
smaller than those found in the HSSC studies
(HSSCSs) (p 0.02) for response in LVEF (0.40
vs. 0.07), LVESV (0.24 vs. 0.06), and LVEDV
(0.53 vs. 0.01) (Fig. 4).
R2 contraction factor arising from outcome variable.
EM-RCTs provided data sufficient to estimate the
R2 contraction factor for the commonly used echo-
ardiographic outcome measures (Table 2) and clinical
esponse markers (Table 3). All 3 echocardio-
raphic outcome variables (LVEF, LVESV, and
LVEDV) have sufficient variability in the control
opulations to give R2 contraction factors that limit
observed R2 to modest values, even if the predictive
dyssynchrony marker or combination algorithm was
perfect and had no variability.
R2 contraction factor arising from the dyssynchrony
ariable. We assessed the published variability of
mechanical dyssynchrony markers between repeated
echocardiograms in the same patient (test–retest
reproducibility) (Table 4). Only 3 studies report the
true test–retest variability needed to calculate the
contraction factor for each dyssynchrony marker. In
one, within-patient variation and between-patient
variation was small (15). The second assessed test–
retest reproducibility of tissue Doppler imaging me-
chanical dyssynchrony markers and presented the R2
contraction factor directly when measured by 2 sepa-
rate readers, giving an average value of 0.35 (16). The
hird randomized patients to biventricular pacing or
edical therapy and reported the change in dyssyn-
hrony indexes remeasured in the control population
70). The mean change and its SD were provided to
s by the authors. Overall, the available contraction
actors range from 0.16 to 0.92, averaging 0.6.
Combined R2 contraction factor. The combined R2
contraction factor between echocardiographic re-
sponse and a dyssynchrony marker is calculated by
multiplication. We estimate that for LVEF it is
0.29 (0.6  0.48); for LVEDV, 0.24 (0.6 0.40);
and for LVESV, 0.30 (0.6  0.50). These are point
estimates and may overestimate or underestimate the
true combined contraction factor. Table 5 displays the
likely values with the most likely region in boldface.
Comparing study design between HSSCSs and EM-RCTs.
We assessed whether studies specified 3 key design
features that limit bias: 1) predictive marker stated
to be measured blinded to outcome; 2) outcome
marker stated to be measured blinded to the pa-
tient’s treatment with biventricular pacing; and“Cardi
“biv
“dys
239
asse
58
Figure 3.
A systema
using base
dict chang3) patients stated to be formally enrolled before the
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1051Table 1. A Comparison of the Baseline Dyssynchrony Variables Found To Predict Response in Externally Monitored Randomized Controlled Trials With
Those Found Highly Skilled Single-Center Studies
Response Measure/
Study/First Author/Year Baseline Variable N
Ischemia DCM Observed
Correlation
Coefﬁcient* R2* 95% CI R2 Ischemia R2 DCM p Valuen % n %
Highly Skilled Specialist Center Studies
∆LVEF
Bax 2003 TDI septal-lateral delay 25 11 44 14 56 0.47 0.22 (0.01–0.53)
Pitzalis 2005 SPWMD 51 11 22 40 78 0.69 0.48 (0.26–0.66)
Marsan 2008 SDI 56 35 62 21 38 0.7 0.49 (0.29–0.66)
Weighted average 0.42 0.40 0.40 0.59
%∆LVEF
Penicka 2004 Sum asynchrony 49 23 47 26 53 0.73 0.53 (0.32–0.70)
Mele 2006 SPWMD 37 16 43 21 57 0.07 0.01 (0.00–0.15)
TPS-SD 37 16 43 21 57 0.86 0.74 (0.55–0.86)
SPWTD 37 16 43 21 57 0.53 0.28 (0.06–0.53)
Lim 2011 SDI 189 63 33 126 67 0.45 0.20 (0.11–0.31)
Weighted average 0.29 0.36 0.34 0.61
∆LVEDV
Pitzalis 2002 SPWMD 20 4 20 16 80 –0.73 0.53 (0.18–0.79)
Weighted average 0.53 0.53 0.53 1.00
∆LVESV
Pitzalis 2002 SPWMD 20 4 20 16 80 –0.7 0.49 (0.14–0.76)
Yu 2003 Ts-SD 30 12 40 18 60 –0.76 0.58 (0.30–0.77)
Bax 2004 TDI septal-lateral delay 80 44 55 36 45 0.84 0.71 (0.58–0.80)
Yu 2004 TDI-Ts-SD 54 22 41 32 59 –0.74 0.55 (0.35–0.71)
TDI-Ts-12 54 22 41 32 59 –0.6 0.36 (0.16–0.56)
SRI-Tsr-SD 54 22 41 32 59 –0.01 0.00 (0.00–0.08)
PSS-12 54 22 41 32 59 –0.28 0.08 (0.00–0.26)
Yu 2005 Ts-SD-12-ejection 56 28 50 28 50 –0.61 0.37 (0.17–0.57)
Ts-SD-6-ejection 56 28 50 28 50 –0.52 0.27 (0.09–0.47)
Ts-12-ejection 56 28 50 28 50 –0.6 0.36 (0.16–0.56)
Ts-6-ejection 56 28 50 28 50 –0.53 0.28 (0.10–0.48)
Porciani 2006 Ts-SD 59 30 51 29 49 –0.32 0.10 (0.00–0.28)
oExcT 59 30 51 29 49 –0.48 0.23 (0.07–0.43)
Yu 2006 TDI-SD-12 55 28 51 27 49 –0.76 0.58 (0.38–0.73)
TDI-SD-6 55 28 51 27 49 –0.63 0.40 (0.19–0.59)
Diff-12 55 28 51 27 49 –0.64 0.41 (0.20–0.60)
Diff-6 55 28 51 27 49 –0.62 0.38 (0.18–0.58)
Sep-Lat 55 28 51 27 49 –0.54 0.29 (0.10–0.50)
Sep-Post 55 28 51 27 49 –0.49 0.24 (0.07–0.45)
Marsan 2008 SDI 56 35 62 21 38 0.6 0.36 (0.16–0.56)
Bank 2009 IVCT 64 40 63 24 37 –0.24 0.06 (0.00–0.21)
TTS-L delay 64 40 63 24 37 –0.14 0.02 (0.01–0.14)
TVIS-L delay 64 40 63 24 37 –0.12 0.01 (0.02–0.13)
SD Rad-6 64 40 63 24 37 –0.2 0.04 (0.00–0.18)
Soliman 2009 SDI (3DE) 90 46 51 44 49 0.56 0.31 (0.16–0.47)
Van Bommel 2010 LV dyssynchrony 361 221 61 140 39 0.38 0.14 (0.08–0.22)
Miyazaki 2010 SPWMD 117 66 56 51 44 0.32 0.10 (0.02–0.22)
S-L delay 117 66 56 51 44 –0.05 0.00 (0.02–0.05)
Tv-SD 117 66 56 51 44 0.15 0.02 (0.00–0.10)
T-SD 117 66 56 51 44 0.38 0.14 (0.05–0.28)
T-dif 117 66 56 51 44 0.43 0.18 (0.07–0.32)
Weighted average 0.22 0.25 0.28 0.76Continued on next page
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1052Table 1. Continued
Response Measure/
Study/First Author/Year Baseline Variable N
Ischemia DCM Observed
Correlation
Coefﬁcient* R2* 95% CI R2 Ischemia R2 DCM p Valuen % n %
%∆LVESV
Mele 2006 SPWMD 37 16 43 21 57 –0.42 0.18 (0.01–0.61)
TPS-SD 37 16 43 21 57 –0.01 0.0001 (0.00–0.11)
SPWTD 37 16 43 21 57 –0.73 0.53 (0.28–0.73)
Delgado 2008 AS-P (radial strain) 161 92 57 69 43 0.41 0.17 (0.07–0.28)
SDt65s 161 92 57 69 43 0.26 0.07 (0.01–0.16)
Lim 2008 SD-TDI 65 25 39 40 61 0.2 0.04 (0.00–0.18)
TSL 65 25 39 40 61 0.2 0.04 (0.00–0.18)
12SD- 65 25 39 40 61 –0.38 0.14 (0.02–0.33)
SDI 100 35 35 65 65 –0.69 0.48 (0.33–0.61)
Wang 2010 RDI-6 basal segments 30 12 40 18 60 0.42 0.18 (0.00–0.46)
RDI-6 mid-LV segments 30 12 40 18 60 0.75 0.56 (0.29–0.76)
RDI-12 (combination) 30 12 40 18 60 0.62 0.38 (0.11–0.64)
Lim 2011 12SD- 189 63 33 126 67 0.18 0.03 (0.00–0.10)
Global strain 189 63 33 126 67 0.2 0.04 (0.00–0.11)
SDI 189 63 33 126 67 0.61 0.37 (0.26–0.48)
Weighted average 0.18 0.21 0.22 0.38
∆NYHA
No HSSCS reported r or R2
of a dyssynchrony
marker to ∆NYHA
∆QoL
No HSSCS reported r or R2
of a dyssynchrony
marker to ∆QoL
Externally Monitored Randomized Controlled Trials
∆LVEF
CONTAK-CD: Marcus 2005 SPWMD 79 57 72 22 28 –0.11 0.01 (0.01–0.10)
MADIT-CRT: Pouleur 2011 Transverse strain
dyssynchrony
761 416 55 345 45 –0.29 0.08 (0.05–0.13)
Weighted average 0.07 0.04 0.05 0.81
%∆LVEF
No EM-RCT reported
this outcome
∆LVEDV
MIRACLE: Cappola 2006 Mitral regurgitation
index
776 463 60 313 40 0.0022 0.000005 (0.00–0.00)
MIRACLE: Cappola 2006 QRS width 776 463 60 313 40 0.12 0.01 (0.00–0.04)
CONTAK-CD: Marcus 2005 SPWMD 79 57 72 22 28 –0.14 0.02 (0.00–0.12)
MADIT-CRT: Pouleur 2011 Transverse strain
dyssynchrony
761 416 55 345 45 0.25 0.06 (0.03–0.10)
Weighted average 0.01 0.02 0.004 0.6
∆LVESV
CARE-HF: Ghio 2009 IVMD 365 168 46 197 54 Not
published
—
CONTAK: Marcus 2005 SPWMD 79 57 72 22 28 –0.1 0.01 (0.02–0.10)
REVERSE: Linde 2009 IVMD 419 236 56 183 44 Not
published
—
MADIT-CRT: Pouleur 2011 Transverse strain
dyssynchrony
761 416 55 345 45 0.25 0.06 (0.03–0.10)
Weighted average 0.06 0.03 0.04 0.8Continued on next page
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1053measurements were made (Table 6). The majority
of the EM-RCTs report some degree of blinding;
almost all of the HSSCSs did not (odds ratio: 70
[95% CI: 6 to 777; p  0.0001] for response
markers; odds ratio: 32 [CI: 3 to 306; p  0.01] for
yssynchrony markers).
To determine the impact of publication bias a
unnel plot was performed (Fig. 5). Study size had
weak but positive relationship with the publishing
arger R2 values (r2 for this relationship 0.25, p
0.01) indicating the evidence of publication bias
favoring positive studies.
To determine the impact of study design that
affected R2, we plotted R2 against study size and the
number of bias-resistance features (Fig. 6). Each
study scored 0 or 1 point for each of 3 features.
When the presence of a feature was unclear, no
point was given. While smaller studies showed a
Table 1. Continued
Response Measure/
Study/First Author/Year Baseline Variable N
Ischem
n
%∆LVESV
No EM-RCT reported
this outcome
∆NYHA
MIRACLE: St John Sutton
2003
IVMD 323 162
∆QoL
MIRACLE: St John Sutton
2003
IVMD 323 162
Weighted average
*Correlation coefﬁcients and coefﬁcient of determination (R2) as reported by st
are shown, arranged by study design. A weighted average for the R2 values is
failure etiology (ischemic or dilated cardiomyopathy [DCM]) were not signiﬁcan
and response marker. Please see the Online Appendix for reference citations.
CARE-HF Cardiac Resynchronization in Heart Failure study; CI conﬁdence inte
HSSCS highly skilled single-center studies; LVEDV left ventricular end-diastolic v
Automatic Deﬁbrillator Implantation Trial With Cardiac Resynchronization Therapy; M
QoL  quality of life; REVERSE  Resynchronization Reverses Remodeling in Systo
Reported Predictability
of ∆LVEF
HSSCS EMRCT
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Figure 4. Comparison of the Reported R2 Values Between Basel
Markers by Different Study Design
Comparison of highly skilled single-center studies (HSSCSs) and ext
R2 values between baseline dyssynchrony markers and echocardiog
cant difference between associations reported by HSSCSs and EM-RCTstendency to report higher R2 values than larger stud-
es, the number of bias-resistance features showed a
tronger influence. Studies designed from the outset to
esist bias never showed high R2 values. Very high R2
values occurred exclusively in studies that described
little or nothing done to resist bias.
D I S C U S S I O N
This article shows how to determine the ceiling on
the sustainable R2 values between any baseline
arker and subsequent response to any interven-
ion, such as biventricular pacing. Readers can use
his ceiling, or contraction factor, to judge whether
n R2 is credible. The greater the test–retest vari-
ability in any predictor and/or response—whether
due to biological factors, measurement error, or
DCM Observed
Correlation
Coefﬁcient* R2* 95% CI R2 Ischemian %
161 50 0.12 0.01 (0.00–0.05)
161 50 0.19 0.04 (0.01–0.09)
0.03 0.03
assessing the ability of baseline mechanical dyssynchrony markers to predict ch
rted, together with the calculated 95% conﬁdence intervals of each R2. R2 values
ifferent. Boldface represents the R2 value calculated from each study between sta
ONTAK-CD CONTAK CD Device Approval Study; EM-RCT externally monitored ra
e; LVEF left ventricular ejection fraction; LVESV left ventricular end-systolic volume
CLEMulticenter InSync ICD Randomized Clinical Evaluation; NYHA New York Hea
ft Ventricular Dysfunction study; other abbreviations are listed in the original public
redictability
LVESV
EMRCT
Reported Predictability
of ∆LVEDV
HSSCS EMRCT
0
0.2
0.4
0.6
0.8
Dyssynchrony Markers and Echocardiographic Response
lly monitored randomized controlled trials (EM-RCTs) for reported
ic markers of response to biventricular pacing. There is a signiﬁ-ia
R2 DCM p Value%
50
50
0.03 1.00
udies ange in response markers
repo when weighted for heart
tly d ted dyssynchrony marker
rval; C ndomized controlled trials;
olum ; MADIT-CRTMulticenter
IRA rt Association classiﬁcation;ted P
of ∆
S
ine
erna
raph(p  0.02).
i
c
i
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1054random noise—the lower the limit on the sustain-
ably observable R2 (20,22).
This approach could be used to screen the plausibility
of any claim of a baseline marker apparently predicting
the effect of any intervention on any variable.
The ceiling to observed R2. Spontaneous variability
n both dyssynchrony markers and response markers
onspire to limit observed R2 to only low values. This
happens with any etiology of heart failure, and for both
single-variable and multivariate risk indexes. HSSCSs
consistently report higher R2 values than EM-RCTs,
and frequently exceed the mathematical ceiling. This
f the Contraction Factor for LVEF, LVESV, and LVEDV in Ext
/Study N
Breakdown of Variability
Unpredictable
Element of
Variability:
Total Var
in Interv
Arm
SD of
Control Arm
SD
Interventi
153 57.0 77.0
735 42.8 66.6
1,366 16.3 31.2
487 23.4 29.5
142 5.1 5.6
55 44.1 46.9
average
154 62.0 76.0
735 50.7 74.5
1,366 14.4 33.2
487 28.0 33.4
142 7.14 5.3
55 47.6 51.9
average
490 10.3 10.4
153 6.2 8.0
735 4.5 8.5
1,366 3.0 5.0
487 6.5 9.3
142 0.99 1.2
55 11.7 15.7
average
r any parameter to the ∆EF in each study is presented for each study. †The ∆LVESV, ∆L
st–retest reproducibility (∆ in controls) had a variance a magnitude smaller than the
nding toward deterioration, and extension of the tail trending toward improvemen
, such as exercise duration (Online Appendix reference 55). The RETHINQ protocol b
itted exclusion of extreme values, as per clinical convention. The published data sugg
l practice because the psychological impact of a deterioration in individual patients i
e scientiﬁcally desired blinded test–retest reproducibility of variables (41–43). Boldfa
center InSync ICD Randomized Clinical Evaluation II; RESPOND  Resynchron
in Normal QRS study; SD  standard deviation; other abbreviations as in Tablesuggests that the HSSCS method is in error. pThis study exposes the prerequisites for reliable
prediction of individual response, which are challeng-
ing. Even a theoretical, perfectly comprehensive dys-
synchrony marker (whether a single-variable or mul-
tivariate algorithm) that incorporates every facet of
responsiveness to biventricular pacing will still have a
low ceiling. This is because it will have spontaneous
variability, as will the marker of response, and these 2
contraction factors multiply to limit R2.
These findings are important because some stud-
es forget the impact of variability within predictors
nd response markers, and so have unrealistic ex-
ally Monitored Randomized Controlled Trials Assessing
Mandatory Ceiling on R2 Value Imposed
Solely by Unpredictable Variability in
Response Measurelity
on
Calculation
Maximal Achievable
R2 Value*
rm R2 95% CI
1–(57/77)2 0.45 (0.33–0.56)
1–(42.8/66.6)2 0.59 (0.54–0.63)
1–(16.3/31.2)2 0.73 (0.70–0.75)
1–(23.4/29.5)2 0.37 (0.30–0.44)
1–(5.1/5.61)2 0.17 (0.07–0.29)
1–(44.1/46.9)2 0.12 (0.008–0.31)
0.50
1–(62/76)2 0.33 (0.21–0.45)
1–(50.7/74.5)2 0.54 (0.49–0.59)
1–(14.4/33.2)2 0.81 (0.79–0.83)
1–(28/33.4)2 0.3 (0.23–0.37)
1–(7.14/5.36)2 –0.77
1–(47.6/51.9)2 0.16 (0.02–0.36)
0.40
1–(10.3/10.4)2 0.02 (0.002–0.05)
1–(6.2/8)2 0.4 (0.28–0.52)
1–(4.5/8.5)2 0.72 (0.68–0.75)
1–(3/5)2 0.64 (0.61–0.67)
1–(6.5/9.3)2 0.51 (0.45–0.57)
1–(0.99/1.22)2 0.34 (0.21–0.47)
1–(11.7/15.7)2 0.44 (0.23–0.62)
0.48
, and ∆LVEF values in RETHINQ have distinctive properties making them unsuitable
r studies. Second, the distributions of ∆ for these echo markers were skewed with
is skew was not present in continuous outcome markers in which only a single
d assessors to allocation but did not report blinding echocardiographers prior to
is latitude was exercised asymmetrically, favoring an appearance of improvement,
ortant. However, from a pure research viewpoint, this skew of ∆s makes the data
presents the calculated R2 from each study.
n in Patients with Heart Failure and a Normal QRS Duration; RETHINQ Table 2. Calculation o ern
Biventricular Pacing
Response Measure
iabi
enti
:
of
on A
∆LVESV
MIRACLE-ICD II
CARE-HF
MADIT-CRT
REVERSE
RETHINQ† 1
RESPOND
Variance weighted
∆LVEDV
MIRACLE-ICD II
CARE-HF
MADIT-CRT
REVERSE
RETHINQ† 6
RESPOND
Variance weighted
∆LVEF
CONTAK-CD
MIRACLE-ICD II
CARE-HF
MADIT-CRT
REVERSE
RETHINQ† 2
RESPOND
Variance weighted
*The maximal possible R2 fo VEDV
for this analysis. First, the te othe
a curtailment of the tail tre t. Th
measurement was possible linde
measurements. It also perm est th
which is common in clinica s imp
unsuitable for evaluating th ce re
MIRACLE-ICD II  Multi izatioectations. Our study shows that many published
n of in Table 1.
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1055studies markedly overestimate the predictive effect
of dyssynchrony markers compared with studies
having formal enrollment and blinded analysis.
This should not be mistaken as a criticism of
workers’ integrity, but rather a failing in all of us in
underestimating the importance of aspects of study
design that might appear superficially uninteresting
or trivial. The time-honored approach of hypothe-
sizing correlations and then finding confirmatory
evidence in one’s local clinical data is incorrect
because it provides results that are not only too high
but actually above the mathematical ceiling. Strong
prediction is sustainable only if both contraction
factors are almost 1. Not only are they nowhere near
1, but comparatively little effort has been put into
establishing what they are.
Can the contraction factor be improved? Only genu-
inely reducing variability in both predictors and
response markers can improve the contraction fac-
tor. Formal blinded test–retest reproducibility
(“other day, other hands, other eyes”) of the markers
must be carried out. Methods should then be
refined or rejected, and the cycle iterated, until a
protocol is obtained that reliably delivers high
reproducibility in independent, blinded hands. It is
the measurement protocol, and not the operators,
that is being tested. If wide test–retest variability is
Table 3. R2 Contraction Factor for Nonechocardiographic Marke
Response
Measure/Study N
Breakdown of
Unpredictable
Element of
Variability:
SD of
Control Arm
6MWD (m)
COMPANION 592 93.0
CONTAK-CD 444 103.8
MIRACLE 171 98.0
Peak VO2 (ml/kg/min)
CONTAK-CD 417 4.3
MIRACLE 303 3.2
QoL score
CONTAK-CD 459 2.0
MIRACLE 403 21.7
%∆QoL
COMPANION 753 23.0
VE/VCO2
MIRACLE 144 5.2
*The maximal achievable R2 column estimates the maximum R2 that any predicto
the calculated R2 from each study.
6MWD 6-minute walk distance; COMPANION Comparison of Medical, Pa
consumption; VE/VCO2  ratio of minute ventilation (VE) and minute productioobserved, then that is the result of the studydesign and it should be reported dispassionately.
Operators should not be blamed for reporting the
truth. Some planners mistake published data on
remeasurement for test–retest reproducibility.
Others collect it too late to change the study
protocol. Worse still, some collect it only under
pressure from journal reviewers after study com-
pletion, at which stage there is overwhelming
pressure to report a narrow variability even if
unrepresentative.
Only markers with strong test–retest reproduc-
ibility should even be considered for expensive trials
of individualized prediction (Table 5). Unless very
much narrower than the population distribution of
these variables, the markers should be rejected or
refined before initiating any major study. Effort
expended on maximizing the ratio of signal
(between-patient genuine variability) to noise
(within-patient variability) is indispensable to im-
proving prediction of response.
Opportunities and limits of replicate averaging. In-
creasing patient recruitment will not raise the ceil-
ing on sustainably observable R2; instead it enforces
the same mathematical ceiling more firmly by
reducing scope for fluke associations.
The impact of noise can, however, be reduced by
making multiple replicate measures per patient and
f Response to Biventricular Pacing
riability
Mandatory Ceiling on R2 Value Imp
Unpredictable Variability in Respo
tal Variability
Intervention
Arm:
Calculation
Maximal Ach
SD of
tervention Arm Point Estimate R2
96.0 1 – (93/96)2 0.06
104.8 1 – (103.8/104.8)2 0.02
109.0 1 – (98/109)2 0.19
4.4 1 – (4.3/4.4)2 0.05
3.2 1 – (3.2/3.2)2 0.00
2.0 1 – (2/2)2 0.00
25.1 1 – (21.7/25.1)2 0.03
26.0 1 – (23/26)2 0.22
6.2 1 – (5.2/6.2)2 0.30
ld ﬁnd when correlated against any of these non-echocardiographic outcome mea
and Deﬁbrillation Therapies in Heart Failure Trial; SDD standard deviation of diff
CO2 (VCO2), a measure of ventilatory response to exercise; other abbreviations asrs o
Va
osed Solely by
nse Measure
To
in
ievable R2 Value
In 95% CI
(0.03–0.10)
(0.002–0.05)
(0.09–0.30)
(0.02–0.10)
(0.004–0.06)
(0.17–0.27)
(0.18–0.43)
r cou sures. Boldface represents
cing, erence (∆); VO2 oxygenusing the average (19,21). However, signal itself is
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1056Table 4. Test–Retest Variability of Dyssynchrony Markers Within Individuals, in Populations Who Are Candidates for Biventricular Pacemaker Implantation*
Dyssynchrony Marker/Study Within-Patient SD
Mandatory Ceiling on R2 Arising From Variability in
Dyssynchrony Marker
R2 95% CIBetween-Patient SD Calculation Limit on R2
Interventricular Mechanical Delay
Pulsed ﬂow Doppler
Burri et al. 2007 Not reported 26 Incalculable
Duncan et al. 2006 Not reported 22 Incalculable
De Boeck et al. 2008 Not reported 25 Incalculable
Bordachar et al. 2010 Not reported 29 Incalculable
Intraventricular Mechanical Delay
Pulsed tissue Doppler
Onset of systolic motion - 2 segment
Burri et al. 2007 Not reported 20 Incalculable
Onset of systolic motion - 4 segment
Penicka et al. 2004 Not reported 37 Incalculable
Onset of systolic motion - (S-L)
Bleeker et al. 2007 Not reported 49 Incalculable
Peak of systolic motion - 2 segment
Burri et al. 2007 Not reported 34 Incalculable
Onset of systolic motion
Penicka et al. 2004 Not reported 37 Incalculable
Burri et al. 2007 Not reported 29 Incalculable
Peak of systolic motion
Burri et al. 2007 Not reported 33 Incalculable
Peak of systolic motion - 4 basal segments
Bax 2004 Not reported 49 Incalculable
Peak of systolic motion - 12 segments
Yu et al. 2003 Not reported 17 Incalculable
Onset of systolic motion - 2 basal segments (S-L)
Soliman et al. 2007 Not reported 48 Incalculable
Peak of systolic motion - 2 basal segments (S-L)
Soliman et al. 2007 Not reported 44 Incalculable
Onset of systolic motion - 2 basal segments (AL-IS)
Palmieri et al. 2010† 32 42 1 –(32/42)2  0.42 (0.13–0.68)
Onset of systolic motion - 2 basal segments (A-I)
Palmieri et al. 2010† 22 27 1 – (22/27)2  0.34 (0.07–0.62)
Onset of ejection
Foley et al. 2011 29 76 1 – (29/76)2  0.85 (0.70–0.93)
Color tissue Doppler
Peak of systolic motion - 2 basal segments (S-L)
Van Bommel et al. 2010 Not reported 51 Incalculable
Peak of systolic motion - 2 basal segments (S-L)
Conca et al. 2009 Not reported 50 Incalculable
Yu et al. 2007 Not reported 54 Incalculable
Faletra et al. 2009 Not reported 75 Incalculable
Peak of systolic motion - 2 opposite segments
Yu et al. 2007 Not reported 32 Incalculable
Peak of systolic motion - 2 segment
Shanks et al. 2010 Not reported 42 Incalculable
Conca et al. 2009 Not reported 50 Incalculable
De Boeck et al. 2008 Not reported 57 Incalculable
Veseley et al. 2008 Not reported not reported — 0.35 (0.01–0.72)Continued on next page
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1057Table 4. Continued
Dyssynchrony Marker/Study Within-Patient SD
Mandatory Ceiling on R2 Arising From Variability in
Dyssynchrony Marker
R2 95% CIBetween-Patient SD Calculation Limit on R2
Peak of systolic motion - 4 segment
Veseley et al. 2008 Not reported Not reported — 0.46 (0.06–0.78)
Peak of systolic motion - 6 segment
Notabartolo et al. 2004 Not reported 137 Incalculable
Conca et al. 2009 Not reported 41 Incalculable
Peak of systolic motion - 12 segment
De Boeck et al. 2008 Not reported 16 Incalculable
Deplagne et al. 2009 Not reported 9 Incalculable
Yu et al. 2007 Not reported 39 Incalculable
Peak of systolic motion - 12 segments SD
Conca et al. 2009 Not reported 15 Incalculable
Yu et al. 2004 Not reported 13 Incalculable
Faletra et al. 2009 Not reported 19 Incalculable
Yu et al. 2007 Not reported 15 Incalculable
Van de Veire et al. 2007 Not reported 16 Incalculable
Peak of systolic motion - 2 basal segments (AL-IS)
Palmieri et al. 2010† 23 81 1 – (23/81)2  0.92 (0.83–0.96)
Peak of systolic motion - 2 basal segments (A-I)
Palmieri et al. 2010† 29 105 1 – (29/105)2  0.92 (0.83–0.96)
Peak of systolic motion - 12 segments SD
Palmieri et al. 2010† 10 22 1 – (10/22)2  0.79 (0.60–0.90)
Peak of diastolic motion - 2 segment
Shanks et al. 2010 Not reported 49 Incalculable
Tissue synchronization imaging
Gorcsan et al. 2004 Not reported 158 Incalculable
Conca et al. 2009 Not reported 15 Incalculable
Faletra et al. 2009 Not reported 35 Incalculable
M-Mode
Septal posterior wall motion delay (SPWMD)
Bleeker et al. 2007 Not reported 119 Incalculable
Pitzalis et al. 2002 Not reported 92 Incalculable
Pitzalis et al. 2005 Not reported 96 Incalculable
Diaz-Infante et al. 2007 Not reported 113 Incalculable
Sassone et al. 2007 Not reported 46 Incalculable
Foley et al. 2011 91.7 99.8 1 – (91.7/99.8)2  0.16 (0.00–0.45)
Lateral wall postsystolic displacement (LWPSD)
Sassone et al. 2007 Not reported 24 Incalculable
3D systolic dyssynchrony index
Marsan et al. 2008 Not reported 0 Incalculable
Faletra et al. 2009 Not reported 3 Incalculable
Conca et al. 2009 Not reported 1 Incalculable
Deplagne et al. 2009 Not reported 0 Incalculable
Liodakis et al. 2010 Not reported 0 Incalculable
Soliman et al. 2009 Not reported 0 Incalculable
Transverse strain
Time to peak transverse strain - 12 segments SD
Pouleur et al. 2011 Not reported 63 Incalculable
Longitudinal strainContinued on next page
Please see the Online App
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1058not increased by replication and so sustainably
observable R2 can rise as high as the underlying R2
but no higher.
When performing replicates for averaging, re-
searchers must avoid the natural temptation to
choose replicates that appear similar, ignoring ap-
parent outliers. Measurements are best made with-
out reference to each other, to maximize the statis-
tical advantages of replicate averaging (22,23).
Researchers should also resist the clinically nat-
ural temptation to choose the replicate most repre-
sentative of the patients’ full clinical status, because
doing so may innocently but powerfully bias the
result toward confirming whatever association the
Table 5. The True Limit to the Observed R2 for the Correlation
Two R2 Contraction Factors*
R2 Contraction Factor
Imposed by Variability in
Response Marker
R2 Contraction Fa
0.1 0.2 0.3
0.1 0.01 0.02 0.03
0.2 0.02 0.04 0.06
0.3 0.03 0.06 0.09
0.4 0.04 0.08 0.12
0.5 0.05 0.10 0.15
0.6 0.06 0.12 0.18
0.7 0.07 0.14 0.21
0.8 0.08 0.16 0.24
0.9 0.09 0.18 0.27
1.0 0.10 0.20 0.30
*The potential R2 contraction factor arising from the variability in dyssynchrony m
arker/Study Within-Patient SD
Mandat
Between-Pa
in - 12 segments SD
Not reported 35
- 16 segments
Not reported 12
d
6 Not reported 16
08 Not reported 26
2010 Not reported 41
od
6 Not reported 10
Combined Interventricular and Intravent
Not reported 65
rt test–retest reproducibility. Where test–retest reproducibility is available, the R2
data for SD within 1 patient are from their Table 3, and the SD across the popu
endix for reference citations.is modest, with the values in bold being the most likely.researcher believes (24). Clinical practice is heavily
dependent on such application of common sense,
but unfortunately this is why routinely acquired
unblinded clinical measurements are unsuitable for
testing whether clinically believed associations are
true. The stronger the belief, and the wider the
range of values available (22,24), the greater the
danger of self-deception.
In practice, replicates are often made a few
seconds apart, but this does not capture variability
over hours and days, or sensitivity to imperceptible
differences in probe position (23). Paradoxically, an
average of replicates would be more consistent
over time if the measurements aggregated within
een LVEF and Dyssynchrony Markers Is a Product of Their
r Imposed by Variability in Dyssynchrony Marker
0.4 0.5 0.6 0.7 0.8 0.9
0.04 0.05 0.06 0.07 0.08 0.09
0.08 0.10 0.12 0.14 0.16 0.18
0.12 0.15 0.18 0.21 0.24 0.27
0.16 0.20 0.24 0.28 0.32 0.36
0.20 0.25 0.30 0.35 0.40 0.45
0.24 0.30 0.36 0.42 0.48 0.54
0.28 0.35 0.42 0.49 0.56 0.63
0.32 0.40 0.48 0.56 0.64 0.72
0.36 0.45 0.54 0.63 0.72 0.81
0.40 0.50 0.60 0.70 0.80 0.90
rs and response markers is shown. The resulting ceiling on observable R2 values
Ceiling on R2 Arising From Variability in
Dyssynchrony Marker
R2 95% CIt SD Calculation Limit on R2
Incalculable
Incalculable
Incalculable
Incalculable
Incalculable
Incalculable
lar Dyssynchrony
Incalculable
traction factor applied by variability in the dyssynchrony marker can be found.
n is from their Table 1. Boldface represents the calculated R2 from each study.Betw
cto
arkeTable 4. Continued
Dyssynchrony M
ory
tien
Time to peak stra
Lim et al. 2011
Strain delay index
Lim et al. 2011
LV pre-ejection perio
Duncan et al. 200
De Boeck et al. 20
Bordeachar et al.
RV pre-ejection peri
Duncan et al. 200
ricu
Pulsed tissue Doppler
Penicka et al. 2004
*Most studies did not repo con
†In the Palmieri study, the latio
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1059Table 6. Differences in Study Design Between EM-RCTs and HSSCSs*
Study
EF/LVESV/LVEDV Measurements
Stated to Be Blinded
Dyssynchrony Measurement
Stated to Be Blinded
Study Measurements Made
Only After Formal Enrollment
EM-RCTs
CONTAK (Marcus 2005) Yes Yes Yes
MIRACLE (Sutton 2003) Yes Yes Yes
CARE-HF (Ghio 2009) Yes Yes Yes
REVERSE (Linde 2008) Yes Yes Yes
MADIT-CRT (Solomon 2010) Yes Yes Yes
MADIT-CRT (Pouleur 2011) Yes Yes Yes
RETHINQ (Beshai 2007) No No Yes
RESPOND (Foley 2011) Yes Yes Yes
Proportion (%) 86 86 100
HSSCSs
Pitzalis et al. 2002 No No Yes
Bax et al. 2003 No Yes Unknown
Yu et al. 2003 No No Yes
Gorcsan et al. 2004 No No Yes
Notabartolo et al. 2004 No No Yes
Penicka et al. 2004 Yes Yes Unknown
Yu et al. 2004 No No Unknown
Pitzalis et al. 2005 No No Yes
Yu et al. 2005 No No Yes
Mele et al. 2006 No No Unknown
Porciani et al. 2006 No No Unknown
Suffoletto et al. 2006 No No Yes
Yu et al. 2006 No No Yes
Gorcsan et al. 2007 No No Yes
Soliman et al. 2007 No No Unknown
Yu et al. 2007 No No Yes
Delgado et al. 2008 No No Unknown
Jansen et al. 2008 No No Yes
Lim et al. 2008 No No Yes
Marsan et al. 2008 No No Yes
Van de Veire et al. 2007 No No Unknown
Bank et al. 2009 No No Yes
Deplagne et al. 2009 Yes Yes Unknown
Soliman et al. 2009 No No Yes
Park et al. 2010 No No Yes
Bordachar et al. 2010 No No Unknown
Kaufmann et al. 2010 No No Unknown
Miyazaki et al. 2010 Yes Yes Yes
Norisada et al. 2010 No No Unknown
Van Bommel et al. 2010 No No Unknown
Wang et al. 2010 No No Unknown
Shanks et al. 2010 No Yes Unknown
Lim et al. 2011 No Yes Yes
Proportion (%) 9 18 >50
*Studies assessing the relationship between echocardiographic dyssynchrony markers and outcome markers were assessed for design features that resist bias.
Speciﬁc statements regarding the blinding of measurements (both baseline dyssynchrony markers and outcome markers) were sought. Statements regarding formal
enrollment of patients into a speciﬁc study prior to measurements being made were also sought. Please see the Online Appendix for reference citations.
Abbreviations as in Tables 1 and 2.
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1060each average were done on separate days (i.e.,
their internal variability had been maximized)
rather than on successive beats (23). Averaging
can only reduce the influence of variability the
full spread of which is captured among the data
points averaged.
The final advantage of replicate measurement, if
“conducted on another day, acquired by other
hands, viewed by other eyes,” is that it exposes
irreproducible markers for early dismissal.
Why some HSSCSs report higher R2 (and higher
than mathematically sustainable limits) than do
EM-RCTs. Several factors may have contributed to
SSCSs’ reporting significantly higher R2 values
han the sustainable values found in EM-RCTs
Fig. 4).
CHANCE ASSOCIATION. High R2 values may have
been found by statistical chance and then published
with preferential enthusiasm. This could occur as
submission bias from research groups and/or accep-
tance bias from journals.
‘RUSSIAN-DOLL’ PUBLICATION. Successive HSSCS
publications from the same site may have overlap-
ping patient cohorts. Patients might understandably
be added to a growing database from which publi-
cations naturally arise. High R2 occurring by chance
in early cohorts would repeatedly contribute to
1/√(N-3)
0 0.05 0.1 0.15 0.2 0.25 0.3
e 5. Evidence of Publication Bias
l plot showing R2 against reciprocal of uncertainty of R2, calcu-
as 1/(N – 3), where N is the sample size. Smaller studies show
R2 values (r2 for this relationship  0.25; p  0.01) indicating the
ce of publication bias favoring positive studies. The combined
nd-design plot in Figure 5 permits comparison of the relative
t of study design and sample size.subsequent publications. cPREFERENTIAL RECRUITMENT OF PATIENTS. Se-
lection of extra patients who have unusually severe
or mild mechanical dyssynchrony, or who have
unusually large changes in the response variable,
will artificially magnify R2.
LACK OF BLINDING. The R2 between mechanical
dyssynchrony markers and response markers can
reliably inform prospective clinical practice only if
each measurement is performed by observers
blinded to the other relevant measurements in that
patient. Mechanical dyssynchrony should be mea-
sured without knowledge of the LVEF, and vice
versa. Dyssynchrony markers are sensitive to adjust-
ment of cursor position, and operators might inad-
vertently “dial in” (25) the expected dyssynchrony if
unblinded. Ventricular function assessment is sim-
ilarly sensitive to choices during acquisition and
during analysis. Clinicians are generally right to
preferentially select plausible rather than implausi-
ble values. Unfortunately, applying this habit in
research is dangerous, because if the clinician al-
ready believes the hypothesis, even minor and
innocent influence will raise R2 dramatically (24).
Concealment of electrocardiography (which shows
biventricular pacing spikes) is essential during anal-
ysis if unbiased LVEF is sought. The majority of
the EM-RCTs report blinding of dyssynchrony and
response measurements (Table 6); almost all of the
HSSCSs did not.
SELECTIVE INCLUSIONOREXCLUSIONOFPARTICULAR
PATIENTS. HSSCSs may receive unusual referral
patterns distorting the distribution of dyssynchrony
markers away from the pattern typically seen by
future clinical practice and in EM-RCTs. Finally,
HSSCSs, if done without the advantage of formal,
sequentially numbered, prospective enrollment of
patients, may end up unintentionally analyzing an
incomplete subset of the population at that center
(24); patients with notably strong concordance be-
tween physiological expectation and clinical re-
sponse are especially unlikely to be forgotten, and
their preferential recollection would persistently
bias R2 upward.
Why do inﬂated reports gain circulation, and how can
recurrences be prevented? It is tempting to blame
ublication bias (i.e., failure to publish negative
tudies). However, the standard funnel plot (Fig. 5)
hows that publication bias is a minority contribu-
or. The overwhelming determinant is the vulner-
bility of the study design to bias, as shown on theR 2
0
0.2
0.4
0.6
0.8
1
Figur
Funne
lated
larger
eviden
size-aombined design-and-size plot (Fig. 6).
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1061The responsibility may lie more properly with us
as an audience for several weaknesses in application
of normal scientific critique.
SOUND-BITE SUSCEPTIBILITY. Our community ac-
epted uncritically the term cardiac resynchronization
herapy. With repetition it became obvious that
uantifying mechanical dyssynchrony (which can
nly refer to ventricular timings because atrium and
entricle should not be synchronous) must quantify
egree of benefit. Obvious, but not necessarily true.
ith experimental investigation of the therapy’s
echanism of action still at an early stage, we might
educe cognitive distortion by using a neutral term
uch as biventricular pacing (26).
AUTHORITY AWE. Physical science audiences judge a
scientific finding by the precise nature of the experi-
ment, the attention to detail, and the track record of
previous claims being verified by others. Cardiologic
audiences may not apply the same level of scrutiny (in
particular, bias resistance is rarely debated) and may
apply the availability heuristic (judging the credibility
of sources from public visibility rather than track
record of reliability). Audiences could usefully restore
habits from their earlier scientific training.
ANNUAL AMNESIA. Hearing each year of novel pre-
ictive markers with progressively more excellent pre-
ictive capacities, cardiologic audiences forget to ask
hat happened to markers of years past. If 2 different
arkers predict excellently, they must agree almost
erfectly; if the latter is not the case, the former is not
redible. Enhanced audience memory would help
esist successive overstatements.
PRACTICAL PARALYSIS. In physical science, any re-
orted efficacious new approach is rapidly tested in
mall experiments by the audience. Cardiologic
udiences may feel unable to do this. Yet simple
xperiments taking only minutes can quickly reject
ome claims. One example is the evaluation of
linded test–retest reproducibility and the applica-
ion of the formulas in this paper. Another is
djustment of interventricular delay across a wide
ange in a single biventricular pacemaker patient,
ith blinded measurement of mechanical dyssyn-
hrony; if this does not show a clear minimum in
his highly controlled environment, it cannot work
cross a population (27,28).
WISHFUL THINKING. We all want our specialty of
chocardiography to be relevant. Reports of successful
pplication are therefore intrinsically popular. But this
s failure to separate our individual skill as echocar-
iographers from the ability of an echocardiographic cechnique to deliver what is claimed. Distinguishing
alsity of a hypothesis from personal inadequacy re-
uires courage but is the hallmark of science.
CRYPTIC COMMENTARY. Even when experts care-
ully review available methods and tabulate that
yssynchrony markers are intensely vulnerable to
oise and sometimes choice of measurement loca-
ion so that there is risk for “dialing in” any desired
evel of dyssynchrony (25), they may be too polite to
xplain the quantitative implication for claims of
esponse prediction (29).
BIAS BLINDNESS. We frequently confuse bias
which arises from study design) with chance
which is addressed by p values). Larger study sizes
1 of 3
2 of 3
Blinded Outcome
Measure, or
Blinded Dyssynchrony,
or Formal enrollment
Study Size (n)
R 2
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Number of
Bias-Resistance
Features in
Study Design
0
0.2
0.4
0.6
0.8
Blinded Out
Measure, a
Blinded Dys
and Formal
3 of 3
0 800 0 800 0 800 0 80
None
Figure 6. Size-and-Design Funnel Plot Showing Impact of Study
Bias Resistance of Study Design on R2 Reported by the Study
The size and study design of studies affect the reported size of the
between baseline mechanical dyssynchrony markers and change in
diographic response markers (e.g., ∆LVEF, ∆LVESV, and ∆LVEDV). Th
design features that resist bias were sought: 1) statements of blind
assessment of the outcome measure; 2) blinded assessment of base
mechanical dyssynchrony; and 3) formal enrolment of patient into
study. Studies with no bias-resistance features (None, red) report a
spectrum of R2 values. Studies designed with multiple bias-resistan
tures (3 of 3, green)—especially if large—report R2 values close to
Abbreviations as in Figure 1.come
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1062statistically significant. This confusion afflicts even
expert audiences, such as those writing guidelines,
who often consider observational studies (if large) to
e the same level of evidence (“B”) as a randomized
ontrolled trial. Yet ironically, larger observational
tudy size increases susceptibility to bias, making
hem less reliable guides to therapeutic decisions.
TEST-RETEST TABOO. We frequently confuse re-
easurement of identical digital images with gen-
ine test–retest reproducibility, entirely ignoring
he majority of variability, which occurs between
eats. Test–retest variability can be readily checked
y clinicians (30).
RETRACTION RELUCTANCE. In science, a finding
beyond the bounds of plausibility, such as faster-
than-light travel (31), is highlighted as suspicious
by the authors even with a p value 2  10–9. The
rror was found to be unrecognized measurement
ias, and the scientific record corrected (32). Our
eld could encourage timely retraction of clinical
eports that are discovered to be unrepresentative,
iving credit to authors who report what went
rong in their own studies.
Clinical implications for mechanical dyssynchrony.
This paper provides a simple method for clinicians
to calculate the ceiling on plausible claims of pre-
dictability of ventricular response. It may seem
surprising that variability in repeated measures can
matter so much because such variability does not
seem to impede normal clinical practice or trials
addressing group mean effects. However, even small
variability inevitably prevents accurate individual-
zed prediction of response.
This approach may seem somewhat mathemati-
al. However, publications stating an R2 or corre-
ation are making a mathematical assertion of asso-
iation strength. This paper shows how the same
athematics that underlie R2 calculations also de-
marcate the upper limit of plausibility, which is far
below 1.0, exposing some assertions as anomalous.
Some may suspect that if ischemic scar or imper-
fect left ventricular lead positioning could be ex-
cluded, mechanical dyssynchrony markers might
provide good prediction. These factors make pre-
diction more difficult, that is, the ceiling is even
lower than we describe here. Our calculations show
that even if scarring, mispositioning, and all other
confounders could be eliminated, the highest sus-
tainable R2 value would still be low.
Nor can multivariable prediction by composite
markers evade these difficulties. Spontaneous vari-
ability in response markers remains and may be bworse for composites of poorly reproducible com-
ponents. Thus composite markers will likely have
an even lower ceiling on R2.
The search for predictive markers stems from a
desire to optimize the resource cost of biventricular
pacing. However, resources expended in identifying
predictors unreliably would be better expended first
screening predictors and response markers for
blinded test–retest reproducibility. Early exposure
of poor reproducibility would forestall reports of
prediction that are destined not to stand the test of
time.
Implications for research into mechanical dyssynchrony.
Our analysis rejects not the concept of mechanical
dyssynchrony, but rather the value of unblinded,
informally enrolled studies of prediction (Fig. 5).
Outcomes are known to be better in those device
recipients who have greater dyssynchrony but ob-
servational study design cannot distinguish whether
the better outcome would have happened without
the device, or occurred as a result of the device. The
continuous-variable analysis of the CARE-HF
(Cardiac Resynchronization in Heart Failure) ran-
domized controlled trial shows both mechanisms
occurring simultaneously (33). Nondevice patients
had progressively better outcomes the more dyssyn-
chrony they had at baseline (33).
Approaches that have worked for addressing
group mean effects cannot be uncritically expected to
determine which individual patients benefit the
most from biventricular pacing. This would need
measurements of the effect of biventricular pacing
on individual patients that have narrow within-
ndividual error bars. Symptoms or outcomes as-
essed in the conventional way are not suitable, but
uantitative physiological measurements could be
eveloped to deliver this (33–35).
Wider implications for cardiologic research. Study de-
ign can overwhelmingly determine study results. In
his example, a “perfect storm” of excellent plausi-
ility—a clear survival benefit from the devices,
linical enthusiasm, unnoticed poor test–retest vari-
bility, underestimated impact of unblinded mea-
urement, and lack of community awareness of
eilings on predictability—has made the literature
s a whole unreliable.
But similar overstatements may be occurring
lsewhere, unnoticed. Our cardiologic community
hould improve its ability to challenge claims. We
ust recognize that study size alone does not
uarantee reliability (36); bias must be actively
emoved by careful planning. We should be em-
oldened to question early pioneering work because
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1063history shows it is often discredited later (37–39).
Negative studies may seem superficially unexciting
to journals, but carefully designed studies replicable
by readers, contradicting prevailing beliefs, are the
lifeblood of genuine science. We should prize not
extreme claims but reliable experiments that can be
checked by readers. When results are incompatible,
groups should collaborate to understand why.
Few real-life outcomes are overwhelmingly de-
termined by 1 variable; almost always, multiple
features (including those that cannot currently be
quantified) matter and interact in a way that cannot
be captured in a single diagnostic marker. There-
fore, we should react with surprise if a single
variable is reported to predict any outcome with
high certainty.
Finally, this recent “bubble market” in mechani-
cal dyssynchrony should inoculate our community
with skepticism for claims of association strength
and encourage the examination of the track record
of whether previous claims have stood the test of
time.
Study limitations. This study is limited by the haste
with which reports of prediction of biventricular
pacing response arrive in the literature before inde-
pendent blinded evaluations of their test–retest
reproducibility of their methods. No study seems to
have performed a series of blinded measurements of
dyssynchrony to permit true reproducibility SD to
be evaluated. We have had to use the SD of
difference between just two, which is an imperfect
estimate of this.
Furthermore, few reports of claimed prediction
of response present sufficient information to deter-
mine the distribution of the change induced by
biventricular pacing, or test–retest reproducibility of
either predictors or outcome measures. We have
used rigorously performed EM-RCTs, which have
control populations to assess the inherent variability
of response markers over time periods over which
response to device implantation is normally mea-
sured. However, these control populations are only
similar (through randomization) to their corre-
sponding intervention populations, rather than be-
ing identical. Therefore, the estimates of the R2
contraction factor may slightly under- or overesti-
mate the true R2 contraction factor. Individual
studies may give an estimate 0, especially if the
true contraction factor is near zero and/or the
statistical characteristics of the  are non-normally
distributed, as might occur when an analysis is
unblinded.These studies had different types of patients with
differing etiologies, echocardiographic criteria, and
outcome measures. This would limit the strength of
a conventional meta-analysis, but it increases the
generalizability of the findings from our study. No
marker was strongly predictive when tested in
bias-resistant designs, despite covering many spec-
tra of patient populations. There was no relation-
ship of the R2 values to the proportion of patients
ho had ischemic etiology of heart failure.
Many different mechanical dyssynchrony markers
ave been assessed, some basic and some sophisti-
ated. They are not all directly comparable. For
penness and completeness, we fully report all of
he markers for which R2 ceiling was calculable
Table 1). Most have only modest values, including
he newer, more sophisticated ones. Markers in-
olving multiple steps to measure have more sources
f variation and are likely to have a worse R2
contraction factor.
Some studies recently report not R2 but area
nder curve or a sensitivity analysis. The underlying
ariability remains, and an equivalent of the R2
contraction factor affects all measures of association.
New studies have chosen to measure alternative
methods of echocardiographic response, such as
global strain. We specifically chose to review the
commonly used echocardiographic response mark-
ers (LVEF, LVESV, and LVEDV). This is be-
cause, first, these markers are commonly measured
by echocardiographic laboratories. Second, they are
the most familiar to clinicians. Third, it has been
accepted that improvement in these is related to
outcome (40). Finally, they have been tested in
formally enrolled EM-RCT settings allowing reli-
able assessment of spontaneous variability. Our
findings, however, are applicable to all future pre-
dictors and response markers. Each must have low
test–retest variability for the contraction factor to be
sufficient for any chance of clinically impressive
prediction of response.
C O N C L U S I O N S
No scientifically conducted study will give reliable
individual patient prediction (e.g., R2  0.5), by
ny current baseline marker of mechanical dyssyn-
hrony, of any current marker of response to biven-
ricular pacing, across a representative range of
atients, with current measurement protocols. Un-
ustainably high R2 values arise through honestefforts in HSSCSs not because the studies are small
N
p
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1064but because they unknowingly have inherently un-
reliable designs.
It may be time to critically reassess the utility of
HSSCS literature on the prediction of ventricular
response to mechanical dyssynchrony. The over-
statement of relationship strength by 5- to 20-fold,
and the large proportion of results exceeding the
mathematically possible ceiling, indicate that un-
blinded studies without formal enrollment have
failed us entirely.
It is not credible to attempt to usefully predict
ventricular response in individual patients, or to
embark on further research into such predictive
power, unless 2 substantial methodologic advances
arrive: 1) protocols for measuring mechanical dys-
synchrony that reliably give high test–retest repro-
ducibility in the hands of multiple centers beyondnization on morbidity and mortality in
1
1
1
nization therapy:and 2) methods for quantifying “response” in a way
that, in patients who undergo no intervention,
shows minimal within-individual change over time,
in blinded externally monitored analysis, over time
periods similar to those over which biventricular
pacing response is typically measured.
The latter may be biologically impossible, in
which case reliable individualized prediction of
response is impossible.
To prevent future bubble markets of ineffective
diagnostics, we should not take seriously any more
unblinded, unenrolled studies that make mathemat-
ically implausible claims.
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